Modernizing Eligibility Criteria for Molecularly Driven Trials.

Kim ES, Bernstein D, Hilsenbeck SG, Chung CH, Dicker AP, Ersek JL, Stein S, Khuri FR, Burgess E, Hunt K, Ivy P, Bruinooge SS, Meropol N, Schilsky RL

Individualized management of advanced bladder cancer: Where do we stand?

Burgess EF

Postchemotherapy surgery for germ cell tumors--what have we learned in 35 years?

Riggs SB, Burgess EF, Gaston KE, Merwarth CA, Raghavan D

Prostate cancer: what did we learn from the 2012 Annual Scientific Meeting of ASCO?

Burgess EF, Raghavan D

Neoadjuvant and adjuvant chemotherapy approaches for invasive bladder cancer.

Raghavan D, Burgess E, Gaston KE, Haake MR, Riggs SB

Prostate cancer serum biomarker discovery through proteomic analysis of alpha-2 macroglobulin protein complexes.

Burgess EF, Ham AJ, Tabb DL, Billheimer D, Roth BJ, Chang SS, Cookson MS, Hinton TJ, Cheek KL, Hill S, Pietenpol JA

Changing perspectives of the role of chemotherapy in advanced prostate cancer.

Burgess EF, Roth BJ